↑ Kroll DJ, Shaw HS, Oberlies NH. Milk Thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007; 6: 110-119
↑ Saller, R.; Melzer, J.; Reichling, J.; Brignoli, R.; Meier, R. An updated systematic review of the pharmacology of silymarin. Forsch Komplementarmed, 2007, 14, 70-80.
↑ Luper, S. A review of plants used in the treatment of liver diseases: Part 1. Altern. Med. Rev., 1998, 3, 410-421.
↑ Schuppan, D.; Jia, J.; Brinkhaus, B.; Hahn, E.G. Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology, 1999, 30, 1099-104.
↑ Gazak R, Walterova D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem 2007; 14: 315-338
↑ Singh RP, Agarwal R. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res 2004; 555: 21-32
